A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

This will be a single-arm, multi-center, open-label phase 1 study. The standard 3+3 design will be used to determine the maximum tolerated dose (MTD) from 4 possible dose levels of Eryaspase in combination with mFOLFIRINOX. We hypothesize that the addition of Eryaspase to FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, and oxaliplatin) will be safe and demonstrate preliminary signs of efficacy in patients with advanced pancreatic cancer. Safety assessments include adverse events, physical examination abnormalities, vital signs, and clinical laboratory tests (including blood chemistry, hematology, and coagulation panel).

Start Date02 Dec 2020

Sponsor / Collaborator

Georgetown University

[+1]

NCT03674242

/ TerminatedPhase 2/3

A Randomized Phase 2/3 Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemotherapy Versus Chemotherapy Alone for the Treatment of Patients With Metastatic or Locally Recurrent Triple-Negative Breast Cancer

This is an open-label, multicenter, randomized, Phase 2/3 study in patients with locally recurrent or metastatic triple-negative breast cancer (TNBC) with no more than one prior systemic therapy for locally recurrent or metastatic disease.

Start Date13 Jun 2019

Sponsor / Collaborator

ERYTech Pharma SA

NCT03665441

/ CompletedPhase 3

A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma

This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease.

Start Date15 Sep 2018

Sponsor / Collaborator

ERYTech Pharma SA

100 Clinical Results associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

100 Translational Medicine associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

100 Patents (Medical) associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

Literatures (Medical) associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

10 Dec 2025·JOURNAL OF CLINICAL ONCOLOGY

TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma

Article

Author: Portales, Fabienne ; Molin, Yann ; Wasan, Harpreet ; Garcia-Carbonero, Rocio ; Marin Vera, Miguel ; Lecomte, Thierry ; Ponz-Sarvise, Mariano ; Hidalgo, Manuel ; Bachet, Jean Baptiste ; Trouilloud, Isabelle ; Hammel, Pascal ; Noel, Marcus ; Macarulla Mercade, Teresa ; Youssoufian, Hagop ; Bockorny, Bruno ; Feliu, Jaime ; Van Cutsem, Eric ; Fountzilas, Christos ; Pazo Cid, Roberto A. ; Tougeron, David ; Cuyle, Pieter-Jan ; Mineur, Laurent ; Gelsomino, Fabio ; Metges, Jean-Philippe ; Van Laethem, Jean-Luc ; Cubillo Gracian, Antonio ; Sauri, Tamara ; Kay, Richard ; Bouché, Olivier ; El-Hariry, Iman ; Forget, Frederic ; Berardi, Rossana ; Guimbaud, Rosine ; Reina, Juan Jose ; Tournigand, Christophe

PURPOSE:

This phase III (ClinicalTrials.gov identifier: NCT03665441 ) study evaluated eryaspase in combination with chemotherapy as second-line treatment in advanced pancreatic ductal adenocarcinoma (PDAC).

PATIENTS AND METHODS:

TRYBECA-1 enrolled patients 18 years and older whose disease progressed on or after 1L chemotherapy. Patients were randomly assigned to eryaspase plus chemotherapy (gemcitabine/nab-paclitaxel or fluorouracil [5-FU], leucovorin [LV], and irinotecan/nanoliposomal irinotecan) or chemotherapy. Treatment was administered in a 4-week cycle for each of the following drugs until disease progression or unacceptable toxicity: eryaspase 100 U/kg intravenously on days 1 and 15; gemcitabine 1,000 mg/m 2 and nab-paclitaxel 125 mg/m 2 intravenously on days 1, 8 and 15; irinotecan 180 mg/m 2 (or nanoliposomal irinotecan 70 mg/m 2 ) intravenously on days 1 and 15; 5-FU 2,400 mg/m 2 as one 46-hour infusion (with a bolus of 400 mg/m 2 ); and LV 400 mg/m 2 intravenously on days 1 and 15. The primary end point was overall survival (OS); secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.

RESULTS:

A total of 512 patients were randomly assigned (n = 255 for eryaspase and n = 257 for chemotherapy alone). Baseline characteristics were balanced between the two groups. There were 420 deaths, with a median OS of 7.5 months for eryaspase and chemotherapy versus 6.7 months for chemotherapy (hazard ratio [HR], 0.92 [95% CI, 0.76 to 1.11]; P = .374); the median PFS was 3.7 months versus 3.4 months (HR, 0.88 [95% CI, 0.73 to 1.07]; P = .196), and the ORR was 16.1% versus 12.5% (odds ratio, 1.35; [95% CI, 0.81 to 2.24]), respectively. Grade ≥3 adverse events (AEs) included neutropenia (25.4% v 20.3%), asthenia (16.9% v 13.8%), and anemia (17.3% v 12.2%) in the experimental versus control arms, respectively.

CONCLUSION:

The addition of eryaspase to chemotherapy did not improve OS, PFS, or ORR. AEs were generally consistent with previous reports of chemotherapy. These results do not support additional development of eryaspase in PDAC.

01 Feb 2023·Cancer treatment reviews

Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review

Review

Author: Dayyani, Farshid ; Macarulla, Teresa ; Wainberg, Zev A ; Johnson, Andrew

INTRODUCTION:

The aim of this review was to characterize the second- and later-line (≥2L) treatment landscape for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

METHODS:

This systematic literature review (PROSPERO: CRD42021279753) involved searches of MEDLINE® and Embase to identify results from prospective studies of ≥2L treatment options for metastatic pancreatic cancer published from 2016 to 2021. Publications were screened according to predetermined eligibility criteria; population-level data were extracted using standardized data fields. Publication quality was assessed according to Grading of Recommendations Assessment, Development and Evaluation (GRADE). The data were analyzed descriptively, grouped by drug class.

RESULTS:

Sixty publications were identified, including 23 relating to comparative trials. GRADE assessment found that, of these 23 trials, 83% reported high or moderate-quality evidence. Of the publications relating to comparative trials, nine (three trials) reported favorable results: the pivotal phase 3 NAPOLI-1 trial for liposomal irinotecan; a phase 3 trial of non-liposomal irinotecan within the FOLFIRINOX regimen; and a phase 2 trial of eryaspase plus chemotherapy.

CONCLUSIONS:

The level of unmet need for ≥2L treatment options for mPDAC remains high. Irinotecan-based regimens currently offer the greatest promise. Investigations into paradigm-changing agents and combination approaches continue.

01 Sep 2022·British journal of haematology

Is asparaginase encapsulated in erythrocytes effective as second‐line treatment in acute lymphoblastic leukaemia?

Letter

Author: Pieters, Rob ; Bertrand, Yves ; van der Sluis, Inge M. ; Baruchel, André

With interest, we have read the recent article by Lynggaard and colleagues.They studied a new formulation of asparaginase encapsulated in erythrocytes (Eryaspase) in acute lymphoblastic leukemia (ALL) patients with a prior hypersensitivity reaction to pegylated E. coli asparaginase.Eryaspase was well-tolerated and most patients had therapeutic asparaginase levels after the first infusion.

News (Medical) associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

18 Oct 2023

·www.labiotech.eu

Erytech Strengthens its Intellectual Property Position in the US

"*" indicates required fields Erytech strengthed its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent. The French biopharmaceutical company develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. The patent entitled “Medicament for the Treatment of Cancer of the Pancreas” has been granted in the US and covers the use of ERY-ASP1, Erytech’s lead product for the treatment of pancreatic cancer (currently in Phase II clinical trial). In accordance with the mechanism of Patent Term Adjustment, the USPTO, the Amercian patent office, has added almost a year of additional protection, bringing the validity of the patent term until October 2029. The patent was filed end 2007 and has since been granted in Europe, Australia, Israel and Singapore. Separately, the USPTO has granted an additional one and a half years of patent term adjustment to Erytech’s core process patent entitled “Lysis/Resealing Process for Preparing Erythrocytes”. This patent had already received almost four years of additional protection according to the American Patent Term Adjustment legislation. Following a recent recalculation of the patent term, requested by Erytech, the USPTO granted one and a half year of additional patent term, bringing the validity of the patent until 2030. So doing the company has in total been able to obtain five years of addition protection for this core patent that covers the heart of its encapsulation technology and products like GRASPA/ERY-ASP. In both cases, the patent term could further be extended with a maximum of five years on the basis of future marketing authorizations. Oncology R&D trends and breakthrough innovations

Phase 2

26 Jun 2023

·www.fiercebiotech.com

Erytech's merger with Pherecydes reaches the finish line after contentious few months

Erytech and Pherecydes will merge to become Phaxiam Therapeutics. Erytech shareholders have sided with the company over a persistent activist investor, greenlighting a merger with Pherecydes months after the proposed deal was first announced. The French biotech said shareholders approved all resolutions that the board was in favor of at a shareholder meeting Friday, the most important of which was a merger with Pherecydes. The joint venture will be called Phaxiam Therapeutics. The wave-through from Erytech’s shareholders marks the end of a contentious few months that pitted the company against activist shareholder Akkadian Partners, which owns roughly 5% of the company’s stock. Akkadian said in May that it thought the proposed value of Pherecydes was “unjustified” following a top-down review of the proposed merger. The investors concluded that the deal did not serve the best interests of Erytech’s shareholders. Erytech has been unwavering in its counter-campaign, calling the statements from Akkadian “disinformation” and saying that the company’s best hope for survival was the merger. Whatever potential Akkadian believed Erytech had without the merger was misguided, the company contended. Erytech has been in a state of flux since the end of 2021 after pivoting the indication of lead asset eryaspase to leukemia following a late-stage flop in patients with pancreatic cancer. Less than a year later, the company dropped the asset all together to focus energy and resources on its drug delivery platform. Merging with Pherecydes will be a reentry into the drug development space—albeit a totally different genre. Pherecydes is developing a series of bacteriophages meant to tackle bacterial infections and antimicrobial resistance. One of the company’s top priorities is a phase 2 phage therapy to treat prosthetic joint infection due to Staphylococcus aureus. The first patient was enrolled a year ago, but there’s been no update to the clinical trial record since, with enrollment still ongoing, according to the record.

Phase 2

23 Jun 2023

·www.globenewswire.com

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutions include: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2022;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2022 to Gil BEYEN and Jean-Paul KRESS and of the compensation policy for executive corporate officers and board members;Renewal of the terms of office as Directors of Hilde WINDELS BV and Mrs. Martine George;Ratification of the appointment of Mr. Didier Hoch and Go Capital (Mrs. Leila Nicolas) as Directors;Appointment of Mr. Robert Sebbag and Mr. Eric Leire as Directors;Approval of the merger with Pherecydes and modification of the corporate name;Delegation of authority to the Board of Directors to carry out a reverse stock-split;Delegations of authority to the Board of Directors to issue shares or other marketable securities convertible into shares to be issued immediately or in the future by the Company, with or without preferential subscription rights for the shareholders;Authorization for the Board of Directors to grant free shares, share subscription and/or share purchase options and/or to issue share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma Group. The full results of all matters voted on at the meeting can be viewed on the Company’s website at www.erytech.com, within the Shareholders Meeting/2023 section under the Investors tab. The merger between Erytech and Pherecydes has been approved by the Combined General Meeting on the basis of an exchange ratio of 4 Pherecydes shares for 15 Erytech shares (the "Merger") which gave full powers to Erytech's Board of Directors to record the definitive completion of the Merger. Erytech shareholders also approved the change of Erytech's corporate name to "Phaxiam Therapeutics". At the Pherecydes Combined General Meeting held today at 1pm, after the Erytech Combined General Meeting, all the resolutions supported by the Pherecydes Board of Directors were approved, including those relating to the Merger. The Erytech Board of Directors met after the Pherecydes Combined General Meeting and acknowledged the completion of the Merger. The Merger took effect today and entails the dissolution of Pherecydes without liquidation. For accounting and tax purposes, the Merger is retroactive to January 1st, 2023. These approvals will enable the creation of Phaxiam Therapeutics, a world leader in phage therapy, to meet the major challenges of public health and European sovereignty. The new Phaxiam Therapeutics shares resulting from the Merger will be admitted to trading on compartment C of Euronext Paris under ISIN code FR0011471135 on June 29, 2023. Settlement and delivery of the new Phaxiam Therapeutics shares will take place on July 3, 2023. In the event that the number of Phaxiam Therapeutics shares to which a Pherecydes shareholder is entitled does not correspond to a whole number of Phaxiam Therapeutics shares, the shareholder will receive the number of shares immediately below, plus the balance in full, a balancing payment in cash based on the price at which the Phaxiam Therapeutics shares corresponding to fractional shares have been sold by the financial intermediaries, within thirty days of the latest of the dates on which the number of Phaxiam Therapeutics shares allotted is recorded in the account of Pherecydes shareholders. Indicative timetable of the Merger process following the Combined Shareholder's Meeting: Erytech's Board of Directors acknowledging the definitive completion of the Merger and deciding on the corresponding capital increase.June 23, 2023Publication of Euronext notice relating to the issue of new shares in consideration for the Merger.June 26, 2023Settlement and admission to trading on the regulated market of Euronext Paris of the new shares issued in consideration for the Merger.July 3, 2023Registration with the SEC and listing on Nasdaq of the American Depositary Shares (ADS) representing the new shares issued as consideration for the Merger.July 3, 2024 About ERYTECH ERYTECH is a biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. On February 15, 2023, ERYTECH announced its intended strategic combination with PHERECYDES to create a global player in extended phage. More detail can be found in the press release. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit www.erytech.com CONTACTS ERYTECH Eric SoyerCFO & COONewCapMathilde Bohin / Louis-Victor DelouvrierInvestor relationsNicolas MerigeauMedia relations+33 4 78 74 44 38investors@erytech.com+33 1 44 71 94 94 erytech@newcap.eu Forward-looking information This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding ERYTECH’s business and regulatory strategy and its evaluation of potential strategic transactions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the failure to achieve certain regulatory and commercial milestones; (2) the inability to maintain the listing of ERYTECH’s shares on the Nasdaq Global Select market and the Euronext regulated market; (3) changes in applicable laws or regulations; (4) the possibility that ERYTECH may be adversely affected by other economic, business and/or competitive factors; (5) the inability to agree to terms on a long-term supply agreement with Catalent; and (6) other risks and uncertainties indicated from time to time in ERYTECH’s regulatory filings. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2021 Universal Registration Document (Document d’Enregistrement Universel) filed with the AMF on April 27, 2022 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 28, 2022 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. Attachment ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

Executive Change

100 Deals associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	NDA/BLA	European Union	ERYTech Pharma SA	-
Pancreatic adenocarcinoma	Phase 3	United States	ERYTech Pharma SA	15 Sep 2018
Pancreatic adenocarcinoma	Phase 3	France	ERYTech Pharma SA	15 Sep 2018
Pancreatic adenocarcinoma	Phase 3	United Kingdom	ERYTech Pharma SA	15 Sep 2018
Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	Phase 3	Belgium	ERYTech Pharma SA	01 Dec 2009
Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	Phase 3	France	ERYTech Pharma SA	01 Dec 2009
Recurrent Adult Acute Lymphoblastic Leukemia	Phase 3	Belgium	ERYTech Pharma SA	01 Dec 2009
Recurrent Adult Acute Lymphoblastic Leukemia	Phase 3	France	ERYTech Pharma SA	01 Dec 2009
T-cell acute lymphoblastic leukemia in relapse	Phase 3	Belgium	ERYTech Pharma SA	01 Dec 2009
T-cell acute lymphoblastic leukemia in relapse	Phase 3	France	ERYTech Pharma SA	01 Dec 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03665441 (TRYBECA-1, Pubmed \| J Clin Oncol)	Phase 3	Advanced Pancreatic Adenocarcinoma Second line	512	Eryaspase plus chemotherapy (gemcitabine/nab-paclitaxel or fluorouracil [5-FU], leucovorin [LV], and irinotecan/nanoliposomal irinotecan)	bmljsnbews(rqwfcemzaa) = shrlfqvgkt ingfdqwwek (ouefbmhegb ) View more	Negative	10 Dec 2025
				Chemotherapy	bmljsnbews(rqwfcemzaa) = nlaamfwxee ingfdqwwek (ouefbmhegb ) View more
NCT04292743 (CTgov)	Phase 1	Advanced Pancreatic Ductal Adenocarcinoma \| Metastatic Pancreatic Ductal Adenocarcinoma	19	Leucovorin Calcium+Eryaspase+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (Eryaspase Dose Level 0 (75 Units/kg) Plus FOLFIRINOX)	qfqxxvwbbu = lbduwisejp dxtwizqcwo (kvhnbtvgqv, ayhngzcfyf - izboeexuqj) View more	-	14 Feb 2025
				FOLFIRINOX+Eryaspase (Eryaspase Dose Level 1 (100 Units/kg) Plus FOLFIRINOX)	qfqxxvwbbu = ihpbsvbatq dxtwizqcwo (kvhnbtvgqv, zvwnuaidyo - ofcnakqlrc) View more
NCT03267030 (CTgov)	Phase 2	Acute Lymphoblastic Leukemia \| Hypersensitivity	55	GRASPA	ueavlxttjw = vjqwnvcowl dcbforpedv (mvqchgwgoq, vcwcqirnby - ushndvhilx) View more	-	15 Mar 2024
NCT04292743 (ASCO 12023 \| ASCO 22023) Manual	Phase 1	Pancreatic Ductal Adenocarcinoma	18	mFOLFIRINOX+Eryaspase	uzkphyhaqp(lxrjmdbxlc) = hypokalemia (22%), fatigue (11%), anemia (6%), hypotension (6%), diarrhea (6%), syncope (6%), and atrial fibrillation (6%). iznolciunw (yrottjcpod )	Positive	31 May 2023
NCT03665441 (Trybeca-1, CTgov)	Phase 3	Pancreatic adenocarcinoma	512	Abraxane+eryaspase+leucovorin+Gemcitabine+Irinotecan+5-FU (Eryaspase Plus Chemotherapy)	mshikwodqe(nyawfipeus) = htbjszyaen cdzykicgsf (ghduckbgmh, azwdhsqwmg - bbccydlyyy) View more	-	28 Sep 2022
				Abraxane+leucovorin+Gemcitabine+Irinotecan+5-FU (Chemotherapy Alone)	mshikwodqe(nyawfipeus) = mbpplrsxkd cdzykicgsf (ghduckbgmh, sqbsyjcrav - kvmkdsebpu) View more
NCT03267030 (Pubmed \| Int J Radiat Oncol Biol Phys) Manual	Phase 2	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Second line	55	eryaspase	hccetsmolo(lpeqvzyhvh) = iqasrlebhw eqoetshhrk (jiadlqjsne, 15.5) View more	Positive	01 Jun 2022
NCT00723346 (Corporate Publications) Manual	Phase 2	Acute Lymphoblastic Leukemia	-	GRASPA	xrdydhahhc(bbyfghwrme) = yralxwzcxa anakbnlone (lmsisathlp ) View more	Positive	06 Apr 2022
NCT01810705 (ENFORCE, CTgov)	Phase 2	Acute Myeloid Leukemia \| Acute Myeloid Leukemia with Myelodysplasia-Related Changes	123	GRASPA (GRASPA)	zsbjnkkfxz(fxdgoduvcc) = xgdaaysgyt cxleaxbcpl (tpdwhvqynt, ifelqomoii - zxfwmsrshm) View more	-	21 Feb 2022
				cytarabine (Control)	zsbjnkkfxz(fxdgoduvcc) = rlopgtteny cxleaxbcpl (tpdwhvqynt, rrbyjowuap - grpeelkhzn) View more
NCT01518517 (GRASPIVOTALL, CTgov)	Phase 2/3	Recurrent Adult Acute Lymphoblastic Leukemia \| Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia \| T-cell acute lymphoblastic leukemia in relapse	85	L-asparaginase	ymdnsvtmuc(lybyuvshsb) = gchbcpqdev meozlyuucv (zdsooitfom, eoqjlesqxr - kqgntsocnh)	-	02 Feb 2022
NCT03665441 (Trybeca-1, ASCO_GI2022) Manual	Phase 3	Advanced Pancreatic Adenocarcinoma Second line	512	chemotherapy+eryaspase	ajqavpsxoe(senhbxrxrq) = rvftaryjwb ssgsezwepw (zjrmxmbmiu, 6.5 - 8.3) View more	Positive	19 Jan 2022
				chemotherapy	ajqavpsxoe(senhbxrxrq) = trpzrhgxhc ssgsezwepw (zjrmxmbmiu, 5.4 - 7.5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis